DeepMatter Group PLC Appointment of Non-Executive Director (8350E)
12 Julio 2021 - 1:00AM
UK Regulatory
TIDMDMTR
RNS Number : 8350E
DeepMatter Group PLC
12 July 2021
12 July 2021
DeepMatter Group Plc
("DeepMatter" or the "Company" or the "Group")
Appointment of Non-Executive Director
DeepMatter (AIM: DMTR), the AIM-quoted company focusing on
digitising chemistry, is pleased to announce that Bryn Roberts has
been appointed to the Board as Non-Executive Director with effect
from 1 August 2021.
Bryn brings a wealth of experience in the pharmaceutical sector
having spent 15 years at Roche, the Swiss multinational healthcare
company. He is currently Senior Vice President and Head of Data
Services at Roche Information Solutions and until recently was
Global Head of Operations, Pharmaceutical Research & Early
Development. As a member of the Pharmaceutical Research & Early
Development Leadership Team he led innovation in disciplines such
as Data Science and Laboratory Automation, including diverse
applications of Digital and Artificial Intelligence (AI)
technologies.
Bryn has a deep understanding of informatics and innovation in
the laboratory, having overseen the development and operation of
Roche's R&D Innovation Centres, including new state-of-the-art
laboratories in Basel, Zurich, Munich and Shanghai. DeepMatter will
seek to leverage his knowledge to further develop its powerful data
platforms and ensure they meet the needs of the world's
pharmaceutical industry, supporting the increased reproducibility,
predictability and sustainability of chemistry.
Bryn is a Fellow at the University of Oxford, an Associated
Faculty member with the University of Frankfurt Big Data Lab,
lectures in medical informatics at the University of Applied
Sciences, Switzerland and sits on a number of prestigious advisory
boards.
Bryn has previously been recognised in the Fierce Biotech IT
list of Top 10 Biotech Techies and the Top 50 Big Data Influencers
in Precision Medicine by the Big Data Leaders Forum.
Karen Bach, Non-Executive Chair of DeepMatter Group, commented:
"I am delighted to welcome Bryn to DeepMatter. To have such a
credible industry expert on the Board is a great vote of confidence
in our team and we look forward to tapping into his wealth of
insight and expertise to drive our offerings forward. An inspiring
leader in the world of informatics, who is pushing the field in
novel data-driven healthcare approaches, Bryn is a perfect fit for
DeepMatter where we enable scientists to use data to discover and
develop medicines that transform patients' lives, reliably and cost
effectively. His expertise will be invaluable as we continue in our
goal of integrating chemistry with technology by building and
commercialising powerful data platforms."
Bryn Roberts, SVP & Global Head of Data Services at Roche,
added: "My career goal is to drive and enable the delivery of
innovative healthcare solutions that address a significant unmet
need. The value of data captured directly in the lab via DeepMatter
and the insights the industry can extract from them will spur
further innovation. I am excited to be joining DeepMatter as my
first commercial Non-executive position and look forward to helping
them on their journey to accelerate scientific computing in the
pharma industry."
Bryn Richard Roberts, aged 53, holds no other listed company
directorships, nor has he held any directorships during the five
years prior to his appointment. He holds no interest in the
ordinary shares of the Company. There are no further disclosures to
be made in accordance with Rule 17 and paragraph (g) of Schedule
2(g) of the AIM Rules for Companies.
For more information, please contact:
DeepMatter Group plc T: 0141 548 8156
Mark Warne, Chief Executive Officer
C anaccord Genuity Limited (Nominated Advisor T: 020 7523 8000
and Broker)
Bobbie Hilliam
Alma PR T: 020 3405 0205
Caroline Forde / Harriet Jackson / Kieran deepmatter@almapr.co.uk
Breheny/ Faye Calow
About DeepMatter Group plc
DeepMatter is building and commercialising the most powerful
data platforms, to enable scientists to easily perform and optimise
chemical reactions, by increasingly integrating chemistry with
technology. Ultimately this will allow the greater use of
artificial intelligence and reaching a point where chemicals can be
autonomously synthesised through robotics.
Visit: www.deepmatter.io and follow @deepmattergroup
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGPUQUMUPGGCG
(END) Dow Jones Newswires
July 12, 2021 02:00 ET (06:00 GMT)
Deepmatter (LSE:DMTR)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Deepmatter (LSE:DMTR)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024